3-(trifluoromethyl)-6-fluoroacetanilide | 349-27-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(trifluoromethyl)-6-fluoroacetanilide
• 英文别名: N-(2-fluoro-5-(trifluoromethyl)phenyl)acetamide；acetic acid-(2-fluoro-5-trifluoromethyl-anilide)；Essigsaeure-(2-fluor-5-trifluormethyl-anilid)；2'-Fluoro-5'-(trifluoromethyl)acetoanilide；N-[2-fluoro-5-(trifluoromethyl)phenyl]acetamide
• CAS: 349-27-9
• 化学式: C₉H₇F₄NO
• 分子量: 221.154
• InChiKey: JXNQWKKPMBQUHS-UHFFFAOYSA-N

物化性质

• 沸点：
  272.7±40.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(trifluoromethyl)-6-fluoroacetanilide 在 盐酸 、 亚硝酸特丁酯 、 硫酸 、 硝酸 作用下， 生成 4-氟-2-硝基三氟甲苯
  参考文献：
  名称：

  Synthesis and QSAR of Herbicidal 3-Pyrazolyl α,α,α-Trifluorotolyl Ethers

  摘要：

  Pyrazole nitrophenyl ethers (PPEs) were recently identified as a novel class of chemistry exerting herbicidal effects by inhibition of protoporphyrinogen IX oxidase. This area of chemistry has been extended to include herbicidal pyrazolyl fluorotolyl ethers. In these compounds, a trifluoromethyl group substitutes for the 4'-nitro group found in the original herbicides and in ''classical'' nitrodiphenyl ether hebicides. Fluoroanisole pyrazole ethers, in which a trifluoromethoxy group replaces the nitro group of diphenyl ether herbicides, are also described. The shift from 4'-nitro to 4'-trifluoromethyl substitution, which is conservative in terms of electrostatics, produced a novel class of herbicide with substantial pre-emergent activity on narrowleaf weed species. Quantitative structure/activity relationships obtained with respect to substitution on the pyrazole ring and at the 3'-position of the fluorotolyl moiety can be summarized effectively by comparative molecular field analysis. In general, 5-methanesulfonyl fluorotoluidide ethers were found to be most active.

  DOI：

  10.1021/jf9601978
• 作为产物：
  描述：

  对氟甲苯 在 盐酸 、 tin 、 五氯化磷 、 硫酸 、 氢氟酸 、 硝酸 作用下， 生成 3-(trifluoromethyl)-6-fluoroacetanilide
  参考文献：
  名称：

  Brown et al., Journal of the Chemical Society, 1949, p. Spl. 113

  摘要：

  DOI：

文献信息

• Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-<i>N</i>-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications
  作者：Michael C. Van Zandt、Michael L. Jones、David E. Gunn、Leo S. Geraci、J. Howard Jones、Diane R. Sawicki、Janet Sredy、Jorge L. Jacot、A. Thomas DiCioccio、Tatiana Petrova、Andre Mitschler、Alberto D. Podjarny

  DOI：10.1021/jm0492094

  日期：2005.5.1

  Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400

  最近鉴定慢性糖尿病并发症的治疗方法的努力导致发现了一系列新型的高效和选择性的3-[（（苯并噻唑-2-基）甲基]吲哚-N-链烷酸醛糖还原酶抑制剂。主要候选化合物3-[（（4,5,7-三氟苯并噻唑-2-基）甲基]吲哚-N-乙酸（利多司他，9）抑制醛糖还原酶，IC（50）为5 nM，是5400倍对醛还原酶的活性较低，醛还原酶是一种与活性醛解毒有关的酶。在为期5天的STZ诱导的糖尿病大鼠模型中，它可降低神经和晶状体山梨糖醇的水平，ED（50）分别为1.9和4.5 mg / kg / d po。在3个月的糖尿病干预模型中（糖尿病1个月，随后2个月以5 mg / kg / d po进行药物治疗），相对于糖尿病对照，它可以使多元醇正常化，并减少运动神经传导速度不足59％。它具有良好的药代动力学特征（F，82％; t（1/2），5.6 h; Vd，0.694 L / kg），并且在目标组织中的良好药物渗透
• 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS
  申请人：Shutske Gregory

  公开号：US20070099955A1

  公开（公告）日：2007-05-03

  The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R 1 , R 2 , R 3 , R 4 , X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.

  本发明提供了公式I的化合物：其立体异构体或其药学上可接受的盐，其中变量R1，R2，R3，R4，X和n如本文所定义。此外，本发明还提供了一种治疗多巴胺相关神经疾病的方法，所述疾病选自神经、心理、心血管、认知或注意力障碍、物质滥用和成瘾行为或其组合，包括向需要此类治疗的患者投与公式I的化合物的治疗有效量。
• SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
  申请人：Washio Yoshiaki

  公开号：US20090291949A1

  公开（公告）日：2009-11-26

  A compound of Formula (I): or a salt or solvate thereof, wherein: One of R 1 and R 2 is H and the other represents —NHCONHR 4 , wherein R 4 represents a phenyl or naphthyl group which may be optionally substituted by one or more substituents independently selected from —C 1-6 alkyl, —C 1-6 haloalkyl, halogen, C 1-6 alkoxy, C 1-6 haloalkoxy, OH, NO 2 , C 3-7 cycloalkyl, indanyl, or R 4 together with the NH to which it is bonded forms a morpholino group; and R 3 is H or NHR 5 wherein R 5 is H, -quinolinyl or -isoquinolinyl, —(CONH) p phenyl wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, -morpholino, —SO 2 NH 2 , and methyl substituted benzothiazole.

  化合物的化学式为（I）或其盐或溶剂化合物，其中： R1和R2中的一个是H，另一个表示为—NHCONHR4，其中R4表示苯基或萘基，可以选择地由一个或多个取代基独立选择从—C1-6烷基，—C1-6卤代烷基，卤素，C1-6烷氧基，C1-6卤代烷氧基，OH，NO2，C3-7环烷基，吲哚基或R4与其连接的NH形成吗啡环基；而R3是H或NHR5，其中R5是H，-喹啉基或-异喹啉基，—（CONH）pphenyl，其中p为0或1，苯基可以选择地由一个或多个取代基独立选择从卤素，—C1-6烷基，—C1-6卤代烷基，-吗啡环基，—SO2NH2和甲基取代苯并噻唑基。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• TYPE II RAF KINASE INHIBITORS
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20150157629A1

  公开（公告）日：2015-06-11

  The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

  本发明涉及一种新的化合物，该化合物能够调节B-raf激酶，并且在治疗各种疾病、障碍或病况中使用这种化合物。